1. Academic Validation
  2. Novel Chemicals Derived from Tadalafil Exhibit PRMT5 Inhibition and Promising Activities against Breast Cancer

Novel Chemicals Derived from Tadalafil Exhibit PRMT5 Inhibition and Promising Activities against Breast Cancer

  • Int J Mol Sci. 2022 Apr 27;23(9):4806. doi: 10.3390/ijms23094806.
Ziyan Yang 1 Tian Xiao 1 Zezhi Li 2 Jian Zhang 1 Suning Chen 3
Affiliations

Affiliations

  • 1 State Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, Fourth Military Medical University, Xi'an 710032, China.
  • 2 Department of Pharmacy, School of Chemistry & Pharmacy, Northwest A&F University, Xianyang 712100, China.
  • 3 Department of Pharmacy, Fourth Military Medical University, Xi'an 710032, China.
Abstract

Breast Cancer seriously endangers women's health worldwide. Protein arginine methyltransferase 5 (PRMT5) is highly expressed in breast Cancer and represents a potential druggable target for breast Cancer treatment. However, because the currently available clinical PRMT5 inhibitors are relatively limited, there is an urgent need to develop new PRMT5 inhibitors. Our team previously found that the FDA-approved drug tadalafil can act as a PRMT5 Inhibitor and enhance the sensitivity of breast Cancer patients to doxorubicin treatment. To further improve the binding specificity of tadalafil to PRMT5, we chemically modified tadalafil, and designed three compounds, A, B, and C, based on the PRMT5 protein structure. These three compounds could bind to PRMT5 through different binding modes and inhibit histone arginine methylation. They arrested the proliferation and triggered the Apoptosis of breast Cancer cells in vitro and also promoted the antitumor effects of the chemotherapy drugs cisplatin, doxorubicin, and olaparib in combination regimens. Among them, compound A possessed the highest potency. Finally, the anti-breast Cancer effects of PRMT5 Inhibitor A and its ability to enhance chemosensitivity were further verified in a xenograft mouse model. These results indicate that the new PRMT5 inhibitors A, B, and C may be potential candidates for breast Cancer treatment.

Keywords

PRMT5 inhibitors; breast cancer; chemotherapy drugs; olaparib; tadalafil.

Figures
Products
Inhibitors & Agonists
Other Products